Platelet P2Y(12) Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model by Thomas, M.R. et al.
Platelet P2Y12 inhibitors reduce systemic inflammation and its 
prothrombotic effects in an experimental human model
Mark R. Thomas1, Samuel N. Outteridge1, Ramzi A. Ajjan2, Fladia Phoenix2, Gurpreet K. 
Sangha1, Rachael E. Faulkner1, Rosemary Ecob1, Heather M. Judge1, Haroon Khan1, Laura 
E. West1, David H. Dockrell3, Ian Sabroe3, and Robert F. Storey1
1Department of Cardiovascular Science, University of Sheffield, United Kingdom
2Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, United Kingdom
3Department of Infection and Immunity, University of Sheffield, United Kingdom
Abstract
Objective—Clinical studies suggest that platelet P2Y12 inhibitors reduce mortality from sepsis, 
although the underlying mechanisms have not been clearly defined in vivo. We hypothesized that 
P2Y12 inhibitors may improve survival from sepsis by suppressing systemic inflammation and its 
prothrombotic effects. We therefore determined whether clopidogrel and the novel, more potent 
P2Y12 inhibitor, ticagrelor, modify these responses in an experimental human model.
Approach and Results—We randomized 30 healthy volunteers to ticagrelor (n=10), 
clopidogrel (n=10) or no antiplatelet medication (controls; n=10). We examined the effect of 
P2Y12 inhibition on systemic inflammation, which was induced by intravenous injection of E.coli 
endotoxin. Both P2Y12 inhibitors significantly reduced platelet-monocyte aggregate formation and 
peak levels of major pro-inflammatory cytokines, including TNFα, IL-6 and CCL2. In contrast to 
clopidogrel, ticagrelor also significantly reduced peak levels of IL-8 and G-CSF and increased 
peak levels of the anti-inflammatory cytokine IL-10. In addition, ticagrelor altered leukocyte 
trafficking. Both P2Y12 inhibitors suppressed D-dimer generation and scanning electron 
microscopy revealed that ticagrelor also suppressed prothrombotic changes in fibrin clot 
ultrastructure.
Conclusions—Potent inhibition of multiple inflammatory and prothrombotic mechanisms by 
P2Y12 inhibitors demonstrates critical importance of platelets as central orchestrators of systemic 
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inflammation induced by bacterial endotoxin. This provides novel mechanistic insight into the 
lower mortality associated with P2Y12 inhibitors in patients with sepsis in clinical studies.
Keywords
Platelets; P2Y12; antiplatelet therapy; systemic inflammation
Introduction
Sepsis is one of the most devastating clinical syndromes in medicine and severe sepsis still 
has a mortality rate of 20-30% and remains resistant to specific pharmacological therapy.1 
Sepsis is characterized by dysregulated systemic inflammatory response to bacterial 
components, such as endotoxin (lipopolysaccharide; LPS).1 Excessive innate immune 
activation causes a pro-inflammatory cytokine storm, extravasation of activated neutrophils 
and disturbances of the coagulation system, leading to collateral host tissue damage and 
increased mortality.1,2 A number of pathological processes, such as sepsis, involve the 
formation of platelet-leukocyte aggregates.3 These platelet-leukocyte interactions have a 
potentially important role in the pathogenesis of inflammation as they augment leukocyte 
production of pro-inflammatory cytokines, leukocyte recruitment and activation of 
coagulation.3,4 However, the overall magnitude of the contribution of platelets to systemic 
inflammation and the pathophysiology of human sepsis is not well defined.
Platelet P2Y12 inhibitors, such as clopidogrel and ticagrelor, inhibit a central ADP-mediated 
amplification pathway and therefore blunt a broad spectrum of platelet functions.5 It is well 
established that the antithrombotic effect of this is beneficial for patients with 
atherothrombosis, which has led to P2Y12 medications becoming some of the most 
commonly prescribed medications worldwide. However, in addition, this inhibits the 
formation of platelet-leukocyte aggregates, which is primarily mediated by inhibition of 
platelet expression of the adhesion molecule P-selectin.3 A very recent cohort study of 
683,421 patients with sepsis has shown that current use of antiplatelet therapy is 
independently associated with a significant reduction in mortality from sepsis (odds ratio 
[OR] 0.78; 95% confidence interval [CI] 0.76 – 0.79; p < 0.001).6 This also corresponds 
with previous observational studies that suggest that clopidogrel reduces mortality from 
sepsis.7,8 However, the mechanisms underpinning this reduction in mortality have not been 
clearly demonstrated in vivo, since animal models of sepsis conflict regarding the 
immunomodulatory effects of clopidogrel, which may be species dependent.9-12
Ticagrelor is a novel P2Y12 inhibitor that causes more potent and consistent P2Y12 
inhibition than clopidogrel13 and also weakly inhibits cellular uptake of adenosine.14 In the 
PLATelet inhibition and patient Outcomes (PLATO) study of over 18,000 patients with 
acute coronary syndromes (ACS), ticagrelor reduced all-cause mortality compared to 
clopidogrel (HR 0.78; p<0.001), which was out of proportion to its incremental 
cardiovascular benefit.15 Intriguingly, ticagrelor was associated with lower mortality related 
to infection (HR 0.67; p<0.05)16,17 and fewer deaths following sepsis and pulmonary 
infections than clopidogrel.18
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We therefore sought to determine the mechanistic impact of P2Y12 inhibitors on 
pathophysiological processes that are central to sepsis responses in humans. We 
hypothesized that P2Y12 inhibitors may reduce mortality from sepsis by suppressing 
systemic inflammation and its prothrombotic effects, mediated by inhibition of platelet-
leukocyte interactions. We hypothesised that the more potent P2Y12 inhibitor, ticagrelor, 
suppresses these responses more potently than clopidogrel. To test these hypotheses in 
humans, we used a well-established model of systemic inflammation, which involves 
intravenous injection of E.coli endotoxin (lipopolysaccharide; LPS) into healthy 
volunteers.19 The particular strength of this unique model is that it allows direct assessment 
of dynamic cellular and molecular pathways that are also major mediators of the 
pathophysiology of sepsis in humans.
Materials and Methods
We randomized 30 healthy volunteers to ticagrelor (n=10), clopidogrel (n=10) or no 
antiplatelet medication (controls; n=10) to determine their effect on systemic inflammation, 
which was induced by intravenous injection of E.coli endotoxin (2 ng/kg lipopolysaccharide 
[LPS]) using a well-established method. Additional details on the Materials and Methods are 
available in the online-only Data Supplement.
Results
Baseline characteristics were comparable in all of the treatment groups (Table I in the online 
data supplement). Thirty healthy volunteers underwent LPS administration (see CONSORT 
flowchart [Fig I] in the online supplement). To avoid any possibility of administering 
intravenous E.coli LPS to a pregnant female, volunteers were only included if they were not 
of childbearing potential; no eligible female subjects volunteered and so all recruited 
volunteers were male. Compliance was assessed from a diary and pill-count and all subjects 
were >90% compliant. After LPS administration, all subjects developed anticipated flu-like 
symptoms and signs of sepsis that peaked at 90 - 180 minutes and resolved within 6 hours 
(Table II in the online data supplement). There were no unexpected adverse reactions.
Both Ticagrelor and Clopidogrel Reduce Peak Levels of IL-6, TNFα and CCL2, whilst 
Ticagrelor Additionally Reduces Peak Levels of IL-8 and G-CSF and Increases Peak Levels 
of IL-10
We assessed systemic inflammation in response to LPS administration by measuring the 
release of major pro-inflammatory cytokines and we determined the modulatory effect of 
P2Y12 inhibitors. Plasma levels of interleukin (IL)-6, TNFα, IL-8, chemokine (C-C motif) 
ligand (CCL)-2, growth colony stimulating factor (G-CSF) and high sensitivity C-reactive 
protein (hsCRP) significantly increased after LPS administration (all p<0.001) (Fig 1). 
Compared to control, both P2Y12 inhibitors had a marked effect on the pro-inflammatory 
cytokine response, reducing peak levels of TNFα (66% reduction [p<0.001] and 60% 
reduction [p<0.001] respectively; Fig 1A), IL-6 (47% reduction [p<0.001] and 28% 
reduction [p=0.001] respectively; Fig 1B), and CCL2 (38% reduction [p<0.001] and 19% 
reduction [p=0.049] respectively; Fig 1C). In addition, ticagrelor, but not clopidogrel, 
significantly reduced peak levels of G-CSF (51% reduction; p<0.001; Fig 1D) and IL-8 
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(29% reduction; p=0.001; Fig 1E) compared to control. Ticagrelor, but not clopidogrel, also 
significantly increased peak levels of the anti-inflammatory cytokine IL-10 compared to 
control (54% increase; p=0.02; Fig 1F). Neither drug significantly modified the hsCRP 
response (Fig 1G).
Ticagrelor Inhibits LPS-induced Platelet-Monocyte Aggregate Formation
Formation of platelet-leukocyte aggregates (defined as leukocyte expression of the platelet 
marker CD42a) amplifies leukocyte release of pro-inflammatory cytokines.3 We therefore 
investigated whether this is a mechanism by which P2Y12 inhibitors reduce systemic 
inflammation. Ticagrelor significantly reduced formation of platelet-monocyte aggregates 
compared to control (21% vs 36%; p<0.001) that occurred 6 hours after LPS administration 
(Fig 2A). Clopidogrel also significantly reduced the formation of platelet-monocyte 
aggregates compared to control (23% vs 36%; p=0.04; Fig 2A). A similar pattern of effect of 
LPS and modulation by the antiplatelet medications was seen in platelet-neutrophil 
aggregate formation, but the effects on platelet-neutrophil aggregate formation were not 
statistically significant (Fig 2B). Platelet P-selectin expression did not significantly change 
after LPS administration (Fig 2C).
Inhibition of platelet P2Y12 ADP receptors was also assessed by measuring platelet 
aggregation, platelet-leukocyte aggregate formation and platelet P-selectin expression in 
response to ADP added ex vivo. Ticagrelor and clopidogrel inhibited ADP-induced platelet 
aggregation, platelet-monocyte aggregate formation, platelet-neutrophil aggregate formation 
and platelet P-selectin expression compared to control at all time points (all p<0.001; Fig 2). 
After randomized treatment, platelet aggregation responses following 5 minutes exposure to 
ADP (final platelet aggregation response) were 2±1%, 14±6% and 70±11% in the ticagrelor, 
clopidogrel and control groups respectively (Fig II in the online supplement). Final platelet 
aggregation responses did not significantly change following LPS administration in any of 
the treatment groups (all p>0.05).
Ticagrelor Increases Neutrophil Counts and Alters Monocyte Dynamics During Systemic 
Inflammation
Since the formation of platelet-leukocyte aggregates facilitates adhesion of leukocytes to the 
endothelium and subsequent extravasation3 we investigated whether inhibition of these 
processes by P2Y12 inhibitors affects leukocyte trafficking. Ticagrelor potentiated the 
increase in neutrophil count, which was significantly higher than controls 2-4 hours after 
LPS administration (p<0.05; Fig 3B) and may have been due to inhibition of non-specific 
sequestration of neutrophils. Clopidogrel did not have a significant effect (Fig 3B). 
Similarly, subjects receiving ticagrelor showed altered monocyte dynamics. Transient 
monocyte sequestration was observed after LPS administration in all volunteers, but 
recovery from this was significantly greater in the ticagrelor and clopidogrel groups (Fig 
3C). Neither P2Y12 inhibitor significantly affected the decrease in platelet count that 
occurred after LPS administration (Fig 3D).
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LPS Induces Prothrombotic Changes in the Fibrin Network that are Attenuated by 
Ticagrelor
The development of a stable fibrin clot represents the critical final stage of thrombosis and 
has the potential to be modified by systemic inflammation20. Turbidimetric assays of 
individual samples showed that fibrin clot maximum absorbance (a measure of clot density) 
and lysis area (a complex measure that assesses both clot formation and lysis) increased 
after LPS administration (p<0.001) (Fig 4A and 4B). Ticagrelor significantly reduced the 
rise in maximum absorbance after LPS administration compared with control (percentage 
increase from baseline of 33% vs. 109%; p=0.02; Fig 4A). Similarly, ticagrelor also reduced 
the increase in lysis area after LPS administration compared with control (percentage 
increase from baseline of 46% vs. 147%; p=0.02; Fig 4B). Clopidogrel had a similar, less 
potent effect that was not statistically significant (Fig 4A and 4B).
More detailed analysis of clot ultrastructure using scanning electron microscopy of pooled 
plasma samples demonstrated that LPS administration resulted in more compact clot 
formation (Fig 5), shown by a significant increase in fibrin clot density (p=0.02) and a 
decrease in fibrin fiber diameter (p=0.01) (Fig 5-6). These changes have been shown to 
increase clot stability and confer resistance to fibrinolysis, both of which contribute to a 
prothrombotic state20. Ticagrelor significantly reduced LPS-induced changes in fiber density 
and fiber diameter (Fig 6), whereas clopidogrel had a similar less potent effect that was not 
statistically significant. LPS induced a marked increase in D-dimer (Fig 4C), which peaked 
at 4 hours (p<0.001). Ticagrelor significantly reduced peak levels of D-dimer by 48% 
compared to control (p<0.001) and clopidogrel significantly inhibited peak levels by 19% 
compared to control (p=0.01).
Discussion
Sepsis is a devastating syndrome for which therapeutic options remain limited. In addition to 
the immediate collateral host tissue damage and mortality caused by sepsis, there is a 20-
fold increase in risk of myocardial infarction and stroke following sepsis by mechanisms 
that are not fully understood.21 Data from clinical studies of platelet P2Y12 inhibitors 
suggest that their use improves mortality from sepsis.6-8 However, animal models of sepsis 
have conflicted regarding the immunomodulatory effect of platelet P2Y12 inhibition on 
sepsis responses9-12, which may be species dependent. We therefore sought to determine the 
mechanistic impact of P2Y12 inhibitors on key molecular and cellular pathways that are 
central to sepsis responses in humans. We investigated the effects of P2Y12 inhibitors on 
leukocyte responses, interactions with platelets that may govern such interactions, and with 
activation of the coagulation system. Our data point to a substantial modulatory effect of 
ticagrelor in particular and place the regulation of platelet activation at the heart of systemic 
inflammation induced by LPS in humans.
To our knowledge, this is the first study to demonstrate marked suppression of response to 
bacterial endotoxemia by platelet P2Y12 inhibitors. Both P2Y12 inhibitors potently reduced 
peak levels of D-dimer and major pro-inflammatory cytokines, including IL-6, TNFα, 
CCL2. In contrast to clopidogrel, ticagrelor also significantly reduced peak levels of IL-8 
and G-CSF and increased the peak level of IL-10 compared to control. Additionally, 
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ticagrelor reduced platelet-leukocyte aggregate formation, altered leukocyte trafficking and 
suppressed prothrombotic changes in fibrin clot ultrastructure. Since these changes in fibrin 
clot structure have been shown to shift the haemostatic balance towards thrombosis,20 this 
represents a novel mechanism by which ticagrelor inhibits the prothrombotic consequences 
of systemic inflammation.
Inhibition of platelet-monocyte aggregate formation demonstrates a mechanism by which 
platelet P2Y12 inhibition reduced systemic inflammation, as the formation of platelet-
monocyte aggregates amplifies monocyte release of pro-inflammatory cytokines, including 
TNFα, CCL2 and IL-8.22,23 Levels of residual platelet P2Y12 reactivity before endotoxin 
administration significantly correlated with subsequent inflammatory and prothrombotic 
response suggesting that the responses were P2Y12-mediated. Ticagrelor and clopidogrel 
belong to different chemical classes, inhibit platelet P2Y12 receptors by different 
mechanisms, and do not have any structural similarities or shared metabolites. From a 
pharmacological perspective, shared non-P2Y12-mediated effects are therefore unlikely. 
P2Y12 receptors were originally identified to be almost exclusive to platelets, although they 
have now also been identified on a limited number of other cell types.24 The extent to which 
leukocytes express P2Y12 still remains unclear, particularly as platelets often contaminate 
isolated leukocyte preparations. In mice, dendritic cells express P2Y12, which appears to 
mediate the secretion of certain cytokines, such as IL-12.24 This offers an additional 
mechanism by which P2Y12 may mediate inflammatory responses, although it has not been 
established whether dendritic cells function in the same way in humans. Recent studies have 
demonstrated that vascular smooth muscle cells (VSMC) also express P2Y12, which 
mediates CCL2 release.25 This may have contributed to the modulatory effect of P2Y12 
inhibition on inflammation, although it has been shown that clopidogrel does not inhibit 
VSMC P2Y12 in rats, possibly due to the potential for nucleated cells to regenerate P2Y12.26 
Ticagrelor is also a weak inhibitor of cellular uptake of adenosine, which increases 
extracellular levels of adenosine.14 Since adenosine can increase macrophage production of 
IL-10, which is associated with a reduction in TNFα and IL-6, this offers a further 
mechanism by which ticagrelor may modify systemic inflammation.27
LPS administration induced platelet-leukocyte aggregate formation, which was inhibited by 
ticagrelor in particular. Platelet-monocyte aggregate formation potentiates monocyte release 
of pro-inflammatory cytokines, including TNFα, CCL2 and IL-8, mediated by NF-κB.22,23 
Additionally, platelet-neutrophil aggregates have been implicated in the pathophysiology of 
acute lung injury.28 Therefore greater inhibition of the formation of platelet-leukocyte 
aggregates represents a mechanism by which ticagrelor may have conferred greater 
protection against excessive innate immune activation during sepsis compared to clopidogrel 
in the PLATO study. Our data show that LPS administration induced an initial neutropenia 
and monocytopenia, which is held to be due to rapid sequestration of leukocytes to the 
endothelium.29 This was then followed by a rapid increase in neutrophil count due to bone 
marrow mobilization. It is notable that neutrophil counts were consistently higher in the 
ticagrelor group compared to the control group, despite lower overall levels of pro-
inflammatory cytokines. This was apparent from very early time points onwards, which 
suggests that this was due to inhibition of leukocyte sequestration, rather than increased 
bone marrow mobilisation, which would tend to have a more delayed effect. It is logical that 
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inhibition of platelet-leukocyte aggregate formation reduces leukocyte sequestration, as 
formation of platelet-leukocyte aggregates upregulates leukocyte expression of adhesion 
molecules and facilitates adhesion to the endothelium.30
In our study, and in other studies, platelet expressed P-selectin was not increased at 30 
minutes or 6 hours after LPS administration. This is likely to be due to the transient nature 
of platelet expression of P-selectin, which is shed by degranulated platelets, although they 
continue to function normally and aggregate.31 It has been asserted that the formation of 
platelet-monocyte aggregates is therefore a more reliable marker of platelet activation in 
vivo.32 The precise cause of thrombocytopenia related to systemic inflammation has still not 
been clarified and the relative contribution of platelet activation is unclear. Neither ticagrelor 
nor clopidogrel significantly attenuated the LPS-induced reduction in platelet count. The 
findings of our study therefore suggest that thrombocytopenia is not entirely mediated by 
platelet activation or the formation of platelet-monocyte aggregates, as P2Y12 inhibitors 
inhibit these processes. The formation of platelet-neutrophil aggregates, or other processes 
where platelet P2Y12 has a less prominent role, may therefore have a greater contribution 
towards thrombocytopenia.
Our study provides a number of novel insights into potential mechanisms for increased risk 
of atherothrombotic events following bacteremia and sepsis.21 Although a prothrombotic 
state is well recognized in sepsis,33 the underlying mechanisms are incompletely understood 
and the relative role of platelets has not been well defined. For the first time, this study 
demonstrates that exposure to bacterial LPS directly causes prothrombotic changes in the 
fibrin network that increase clot stability and confer resistance to fibrinolysis, both of which 
shift the haemostatic balance towards thrombosis 20. Platelet P2Y12 inhibitors inhibited 
these prothrombotic effects of LPS and our results suggest that this may have been due to a 
reduction in levels of pro-inflammatory cytokines, as TNFα in particular has been shown to 
be a potent activator of the coagulation system in vivo.34 The greater overall effect of 
ticagrelor on these pathways compared to clopidogrel suggests a mechanism by which 
ticagrelor reduced cardiovascular death following infection in the PLATO study. The 
combined effect of ticagrelor, in particular, on leukocyte production of cytokines, leukocyte 
sequestration, platelet-leukocyte aggregate formation and subsequent changes in fibrin clot 
ultrastructure point to a substantial role for platelets in orchestrating the innate immune 
response to LPS. This suggests potential for timed platelet P2Y12 inhibition in patients with 
infection to modify the risk of sepsis and associated thrombotic complications. In this study 
and in observational clinical studies, subjects were already taking P2Y12 inhibitors at the 
onset of systemic inflammation and sepsis respectively. However, no studies have 
established the effect of administration of P2Y12 inhibitors to patients with established 
sepsis. The greater infectious and inflammatory burden of established sepsis presents a 
different balance of risks and benefits and it is critical that any studies that investigate these 
medications in the context of sepsis carefully address the optimal timing of administration. 
In sepsis, excess fibrin deposition and impaired anticoagulant mechanisms lead to 
exhaustion of the coagulation cascade, causing coagulopathy and bleeding.1 Although 
antiplatelet medications normally exacerbate bleeding, this may therefore be counter-
balanced by attenuating the prothrombotic state that drives the development of coagulopathy 
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during sepsis. In support of this, antiplatelet medications are not associated with excess 
bleeding in patients with sepsis in observational studies.7 However, it is important to 
recognize that patients with established coagulopathy may have their antiplatelet 
medications discontinued in these studies and are less likely to benefit from these agents.
Ticagrelor and clopidogrel are some of the most commonly prescribed medications 
worldwide, due to their established benefit in the management of atherothrombosis. The 
results of this study therefore have potentially important clinical implications for millions of 
patients who are currently treated with these medications. In addition, there is great interest 
in the use of specific immunomodulatory therapy for the treatment of acute coronary 
syndromes.35 The results of our study elucidate the background anti-inflammatory effects of 
medications that are already used for acute coronary syndromes. This is crucial information 
for determining the most appropriate inflammatory targets in the design of novel treatment 
strategies.
A limitation of this study is that clopidogrel has a less potent inhibitory effect in patient 
populations compared to its effects in healthy volunteers.36 This is not the case for 
ticagrelor, which has a consistently potent effect in patient populations.37 Therefore the 
results of this study may actually underestimate the additional efficacy of ticagrelor 
compared to clopidogrel in suppressing systemic inflammation in patients. Whilst this study 
demonstrates the key cellular and molecular pathways by which platelet P2Y12 inhibitors 
could reduce mortality from sepsis, further randomized human studies are needed to 
determine whether this improves outcomes in patients.
In conclusion, this study demonstrates for the first time that clopidogrel and ticagrelor have 
a marked effect on multiple critical mechanisms involved in the pathophysiology of sepsis. 
This suggests a promising line of investigation for novel applications of P2Y12 inhibitors in 
a syndrome that has proved elusive to almost all previous pharmacological strategies. The 
greater overall effect of ticagrelor compared to clopidogrel also provides critical mechanistic 
insight into the lower mortality following sepsis observed in the ticagrelor group compared 
to the clopidogrel group in the PLATO study.
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G-CSF Growth colony stimulating factor
hsCRP high sensitivity C-reactive protein
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Significance
The main findings of this study were that platelet P2Y12 inhibitors, such as ticagrelor and 
clopidogrel, potently suppress systemic inflammation and its prothrombotic effects in an 
experimental human model. This provides critical mechanistic insight into the findings of 
clinical studies that have shown that treatment with platelet P2Y12 inhibitors is associated 
with a reduced mortality from sepsis. This suggests the potential for novel strategies for 
the treatment of sepsis, which has a high mortality and has remained elusive to almost all 
other therapeutic approaches.
This is the first study to demonstrate that platelet P2Y12 inhibitors reduce systemic 
inflammation induced by bacterial endotoxin in vivo. Ticagrelor and clopidogrel are some 
of the most commonly prescribed medications worldwide, due to their established benefit 
in the treatment of acute coronary syndromes and atherothrombosis. The findings of this 
study are therefore important for cardiologists and the millions of patients worldwide 
who are already treated with these medications for atherothrombosis.
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Figure 1. Levels of pro-inflammatory cytokines TNFα (A), IL-6 (B), CCL2 (C), G-CSF (D), IL-8 
(E), IL-10 (F) and hsCRP (G) before and after 1 week of antiplatelet treatment and following 
LPS administration (t = 0 hours)
Data expressed as mean ± SEM (n=10 in each group). The overall effect of LPS and the 
effect of ticagrelor and clopidogrel (both compared to control at each time point) determined 
using 2-way ANOVA with Dunnett’s correction for multiple comparisons for the cytokines 
(*p<0.05, **p<0.01 and ***p<0.001). For hsCRP, the effect of ticagrelor and clopidogrel 
compared to control was determined using ANOVA of AUC.
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Figure 2. Platelet-monocyte (A) and platelet-neutrophil (B) aggregate formation and platelet P-
selectin expression (C) at baseline, immediately before LPS administration and 6 hours after 
LPS administration, in unstimulated samples and samples stimulated by 30 μM ADP ex vivo
Data expressed as mean ± SEM (n=10 in each group). The overall effect of LPS and the 
effect of ticagrelor and clopidogrel (both compared to control at each time point) were 
determined using 2-way ANOVA with Dunnett’s correction for multiple comparisons 
(*p<0.05, **p<0.01 and ***p<0.001).
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Figure 3. Leukocyte (A), neutrophil (B), monocyte (C) and platelet (D) counts before and after 1 
week of antiplatelet treatment and following LPS administration (t = 0 hours)
Data expressed as mean ± SEM (n=10 in each group). The overall effect of LPS and the 
effect of ticagrelor and clopidogrel (both compared to control at each time point) were 
determined using 2-way ANOVA with Dunnett’s correction for multiple comparisons 
(*p<0.05, **p<0.01 and ***p<0.001).
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Figure 4. Levels of D-dimer (A) and fibrin clot maximum absorbance (B) (a measure of clot 
density) and lysis area under the curve (C) (a complex measure that assesses both clot formation 
and lysis) determined by turbidimetry (expressed as percentage change from baseline value) 
following treatment and LPS administration
Data expressed as mean ± SEM (n=10 in each group). The overall effect of LPS and the 
effect of ticagrelor and clopidogrel (both compared to control at each time point) were 
determined using 2-way ANOVA with Dunnett’s correction for multiple comparisons 
(*p<0.05, **p<0.01 and ***p<0.001).
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Figure 5. Representative electron microscope images of fibrin clots formed from plasma ex vivo 
in each treatment group immediately before and 6 hours after LPS administration
Clots were prepared in duplicate and 4 photographs were taken of each clot at each time 
point. In the control group, there is an increase in fibrin network density following LPS 
whereas in the clopidogrel and ticagrelor groups this is not apparent.
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Figure 6. Fibrin fiber diameter (A) and fibrin network density (B) (determined by electron 
microscopy) following LPS administration
Data expressed as mean ± SEM (n=8 in each group). The overall effect of LPS and the 
effect of ticagrelor and clopidogrel (both compared to control at each time point) were 
determined using 2-way ANOVA with Dunnett’s correction for multiple comparisons 
(*p<0.05, **p<0.01 and ***p<0.001).
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